Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study

Journal of Dermatology

Volumn 43, Issue 9, 2016, Pages 1011-1017

  Imafuku, Shinichi ^a   Honma, Masaru ^b   Okubo, Yukari ^c   Komine, Mayumi ^d   Ohtsuki, Mamitaro ^d   Morita, Akimichi ^e   Seko, Noriko ^f   Kawashima, Naoko ^f   Ito, Saori ^f   Shima, Tomohiro ^f   Nakagawa, Hidemi ^g  

^a FUKUOKA UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e NAGOYA CITY UNIVERSITY   (Japan)

^f NOVARTIS PHARMA K K   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

clinical global impression; generalized pustular psoriasis; interleukin 17A; Psoriasis Area and Severity Index; secukinumab

Indexed keywords

CYCLOSPORIN; ETRETINATE; METHOTREXATE; PREDNISOLONE; SECUKINUMAB;

ADULT; ARTHRALGIA; ARTICLE; BOWEN DISEASE; CELLULITIS; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED PUSTULAR PSORIASIS; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); JAPANESE DERMATOLOGICAL ASSOCIATION SEVERITY INDEX SCORE; LIVER DYSFUNCTION; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PSORIASIS AREA AND SEVERITY INDEX; PUSTULAR PSORIASIS; RHINOPHARYNGITIS; SKIN DISEASE ASSESSMENT; TOXIC HEPATITIS; UPPER GASTROINTESTINAL BLEEDING; URTICARIA;

EID: 84985920039     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13306     Document Type: Article

References (13)

1. Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol 2015; 173: 239–241.
2. Sugiura K, Takemoto A, Yamaguchi M et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 2013; 133: 2514–2521.
3. Takahashi H, Nakamura K, Kaneko F et al. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002–2008. J Dermatol 2011; 38: 1125–1129.
4. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509.
5. Japanese Dermatological Association, 2015. Japanese Dermatological Guidelines for General Pustular Psoriasis. Available from URL: https://www.dermatol.or.jp/uploads/uploads/files/guideline/1372913421_3.pdf.
6. Yilmaz S, Cicek N, Coskun M et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res 2012; 304: 465–469.
7. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015; 27: 127–133.
8. Leonardi CL, Gordon KB. New and Emerging Therapies in Psoriasis. Semin Cutan Med Surg 2014; 33: S37–S41.
9. Sanford M, McKeage K. Secukinumab: first global approval. Drugs 2015; 75: 329–338.
10. Ohtsuki M, Morita A, Abe M et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41: 1039–1046.
11. Blauvelt A, Prinz J, Gottlieb A et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172: 484–493.
12. Fujisawa T, Moriya C, Shibuya Y et al. Combination therapy of infliximab and granulocyte/monocyte adsorption apheresis for refractory pustular psoriasis with psoriatic arthritis. Acta Derm Venereol 2013; 93: 364–365.
13. Mabuchi T, Manabe Y, Yamaoka H et al. Case of generalized pustular psoriasis with end-stage renal disease successfully treated with granulocyte monocyte apheresis in combination with hemodialysis. J Dermatol 2014; 41: 521–524.